PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definitive Agreement") with Canurta Limited Partnership ("Canurta") and each of the limited partners of Canurta, the parent en
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-10-30 9:00 AM EDT | PharmaDrug Inc.
Quantum BioPharma Ltd. Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareh
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-29 9:00 PM EDT | Quantum BioPharma Ltd.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
Red Light Holland Secures Second United States Controlled Substances Import Permit for the Company's Psilocybin Through FDA-Compliant, DEA-Registered Partner Irvine Labs
Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-10-14 8:34 AM EDT | Red Light Holland Corp.
Numinus Wellness Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as the Company's independent auditor of its own initiative, and that MNP LLP ("MNP") has been eng
2025-10-10 5:00 PM EDT | Numinus Wellness Inc.
Psyched Wellness Provides Comprehensive Investor Update
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company specializing in the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to provide the following corporate update to its investors. Product Development & Launches Santa - Dietary Supplement Shot Following the initia
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2025-10-09 7:30 AM EDT | Psyched Wellness Ltd.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2024 Results with 65% Revenue Growth, Positive Cash Flow and Double-Digit Operating Margin; Continued Growth in 2025; First Half Revenues Up 31% Year-Over-Year
Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's leading hemp- and CBD-based retail platforms, is pleased to report the audited financial results of Hanf.com for the fis
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-08 9:37 AM EDT | Neural Therapeutics Inc.
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Red Light Holland Receives Official Psilocybin COA Through FDA-Compliant, DEA-Registered Partner, Irvine Labs, USA
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announced today that it has received an offici
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-09-30 8:06 AM EDT | Red Light Holland Corp.
Quantum BioPharma Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-26 8:00 PM EDT | Quantum BioPharma Ltd.
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17t
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-23 12:16 PM EDT | Neural Therapeutics Inc.
Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk
Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") whi
Biotechnology, Cannabis, Health, Psychedelics
2025-09-08 3:18 PM EDT | Optimind Pharma Corp.
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States. The number of common share
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-08 7:00 AM EDT | Optimi Health Corp.
Optimind Pharma Announces Termination of Letter of Intent
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited ("Monjin"), with respect to the Company's acquisition of Monjin, has been mutually terminated by the parties. The Company is continuing to evaluate and review alternative acquisition opportunities. About the
Biotechnology, Cannabis, Health, Psychedelics
2025-09-04 4:00 PM EDT | Optimind Pharma Corp.
Red Light Holland's Wholly Owned Subsidiary Happy Caps Mushroom Farm Secures Continued Safeway Partnership to 123 Stores Across Two Seasonal Programs in the U.S.
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce its secured an expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farms ("Happy Caps") with Albertsons Companies and it's Safew
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-09-04 8:01 AM EDT | Red Light Holland Corp.
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia, which are now being prescribed to patients with Treatment-Resistant Depression ("TRD") under the Authorised Prescriber Scheme. The initial shipment of 1,000 psilocybin capsules, each conta
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-03 7:30 AM EDT | Optimi Health Corp.
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 "). "Th
2025-09-03 7:00 AM EDT | Numinus Wellness Inc.
Red Light Holland Reports First Quarter 2026 Results
Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announces its financial and operational results f
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-08-28 7:40 AM EDT | Red Light Holland Corp.
Red Light Holland Updates Bitcoin Balance Sheet Strategy
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, today announced an update on its Bitcoin balance sheet strategy.
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-08-26 8:23 AM EDT | Red Light Holland Corp.
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").
2025-08-20 5:24 PM EDT | Numinus Wellness Inc.